Balaji Amines Limited (BALAMINES) climbed +6% to ₹2172.1 on the NSE today, reflecting a technical bounce from support rather than a breakout. The stock has transitioned from a bounce from support to consolidating down, indicating a weak structure. This move is specific to BALAMINES and does not align with broader sector momentum in specialty chemicals.

Technical setup — trendlines & DMA

The current 6-month trendline structure shows BALAMINES trading above the 6-month support trendline at ₹1959.04, which is 9.81% below today’s price, but well below the 6-month resistance trendline at ₹2525.35. The stock is currently in a breakdown phase, with the 50-DMA at ₹2154.9 above the 200-DMA at ₹1447.2, suggesting a positive but recovering trend. BALAMINES is trading in the upper third of its 52-week range, indicating that a significant portion of its move is already priced in.

Fundamentals & business context

With a PE of 32.5 and profit margins at 13.4%, BALAMINES’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings do not justify the high PE ratio. Institutional ownership stands at a low 2.3%, indicating that smart money is cautious about this name. There was no NSE catalyst today driving the move.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weak stock. The strongest signals include bullish sentiment with a 1.85x higher average volume on up days compared to down days, and a positive year-over-year gain of 32.2%. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.54% offers little income to investors, despite the company’s excellent financial health with a debt-to-equity ratio of 0.00.

Company outlook

Management outlined an optimistic forward guidance for BALAMINES, targeting a 25% to 30% volume growth in FY27 and sustaining EBITDA between 22% to 23% on total sales. The company aims to achieve a revenue target of ₹3,000 crores by FY28. Key growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, BALAMINES plans a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment and several greenfield and brownfield projects expected to be commissioned throughout FY27.

Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.

Balaji Amines Limited (BALAMINES) breaks below support, falling -5% to ₹2125.6 on the NSE on 31 Jul 2026. The move comes as the stock has breached its 6-month support trendline, signaling a breakdown in the short-term trend. Balaji Amines operates in the specialty chemicals segment within the basic materials sector, and today’s decline appears to be company-specific rather than a sector-wide phenomenon.

Technical setup — trendlines & DMA

The current 6-month support trendline for Balaji Amines was at ₹2436.56, and the stock has fallen 14.63% below this level, indicating a breakdown. Resistance is at ₹2525.35, which is 18.81% above the current price. The 50-DMA is at ₹2113.0, slightly below today’s price, while the 200-DMA is at ₹1419.4, showing a significant 58.05% increase from this longer-term average. The stock is currently in the upper third of its 52-week range, suggesting that a substantial portion of its yearly highs is still priced in.

Fundamentals & business context

With a PE of 35.7 and profit margins at 13.4%, Balaji Amines’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings and growth trajectory suggest a cautious approach. Institutional ownership stands at a mere 2.3%, indicating that the ‘smart money’ is not heavily invested in this name. There was no specific NSE catalyst today to explain the move.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Balaji Amines. The strongest signals include a bullish trend, with the 50-day average above the 200-day average, and bullish sentiment over the last 30 days, where up days saw 2.24 times the volume of down days. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.48% offers little income for investors, while the high public ownership of 41.57% suggests higher volatility risk.

Company outlook

Management has provided forward-looking guidance indicating 25% to 30% volume growth in FY27 and EBITDA sustainability between 22% to 23% on total sales. The company targets INR3,000 crores in revenue by FY28 and plans a capital expenditure of INR275 crores to INR290 crores for the current year. Growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment is planned in a phased manner.

Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.

Balaji Amines Limited (BALAMINES) announced its unaudited financial results for the quarter ended June 30th, 2026. The company reported consolidated revenue from operations of ₹461 crore, up 14% from ₹403 crore in Q4FY26. EBITDA stood at ₹121 crore, up from ₹102 crore in Q4FY26, and net profit was ₹78 crore, up from ₹65 crore in the previous quarter.

Operational Performance

The company’s total volumes stood at 21,587 MT for Q1 FY27 as against 27,570 MT in Q1 FY26. On a standalone basis, the company remains a zero-debt entity. The EBITDA margin for Q1FY27 was 26%, up from 25% in Q4FY26 and 17% in Q1FY26. The PAT margin for Q1FY27 was 17%, up from 16% in Q4FY26 and 10% in Q1FY26.

New Projects and Expansions

Following the successful commissioning of its 100,000 TPA Dimethyl Ether (DME) plant, Balaji Amines continues to execute its growth roadmap. The DME plant marks the company’s strategic entry into alternate fuel applications, catering to LPG blending and aerosol propellant markets. The company’s next phase of expansion includes the commissioning of N-Methyl Morpholine (NMM) and the Acetonitrile (ACN) capacity expansion during FY27.

Balaji Speciality Chemicals Limited continues to advance its ₹750 crore phased expansion programme, which has been accorded Mega Project Status by the Government of Maharashtra. The expansion is aimed at establishing an integrated specialty chemicals platform with the manufacture of high-value products including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), EDTA, EDTA-2Na, and downstream EDA derivatives.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, ‘We have commenced FY27 on a strong note, delivering healthy operational and financial performance supported by improved demand across key end-user industries and sustained execution across our businesses.’ Looking ahead, the company remains confident in its growth outlook backed by a healthy order pipeline, improving demand environment, ongoing capacity additions, and a disciplined approach to execution.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Balaji Amines Limited

Balaji Amines Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Balaji gains 72.3% over three months and trades near its 52-week highs. Revenue contracts at -15.6% CAGR. That signals structural headwinds, not a short-term blip. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 72.3% in three months. Yet revenue grows at only -15.6% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Balaji Amines Limited.